ArticleExperimental hematology2016

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Ilaria Ceglia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.